Galapagos appoints David Smith as CEO of Service Division
(Thomson Reuters ONE) -
Mechelen, Belgium; 20 August 2013 - Galapagos NV (Euronext: GLPG) announced
today the appointment of David Smith as CEO of the service division and member
of the Galapagos Executive Committee.
Galapagos' service division comprises BioFocus and Argenta. Together with
Fidelta, Galapagos has three leaders in premium drug discovery services for
pharma, biotech, universities, and patient foundations. Galapagos' service
division and Fidelta meet clients' needs for drug discovery tools and expertise
by providing a full range of services, from target discovery through to delivery
of pre-clinical candidates, including compound libraries, medicinal chemistry
and ADME/PK services. To further optimize the performance and ensure further
growth of this division and Fidelta, a CEO position has been created, to be
filled by David Smith. Chris Newton, John Montana and Phil Dudfield will lead
BioFocus, Argenta, and Fidelta, respectively, as Managing Director; they will
report to David Smith. David will become member of the Galapagos Executive
Committee and report to Galapagos CEO Onno van de Stolpe.
David Smith joins Galapagos from the Cambridge University Hospitals where he was
Director Finance for six years. Previously he was CFO of Galapagos for two
years, during which he played a key role in several M&A projects to build the
service division between 2005 and 2007. Prior to that, at AstraZeneca he held
Marketing Company CFO roles (where he was also a Board member of the AstraZeneca
Dutch Holdings Group) and a number of strategic and integration functions within
R&D; at Coopers & Lybrand (now PriceWaterhouseCoopers) he was audit manager to a
variety of industries and international clients in Dubai, and post qualification
as a Chartered Accountant in Leeds he ran a number of companies in
administration. David holds a degree in Molecular Biophysics from the
University of Leeds.
"We welcome David back to Galapagos," said Onno van de Stolpe, Chief Executive
Officer, Galapagos. "David brings valuable strategic and operational experience
to the Galapagos Group, and he is already familiar with the services business
from his previous role at the Company. We have confidence that he can take the
successful Service division to the next level."
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with a large pipeline of four clinical, six pre-clinical, and 20 discovery
small-molecule and antibody programs in cystic fibrosis, inflammation,
antibiotics, metabolic disease, and other indications.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment
of rheumatoid arthritis and potentially other inflammatory diseases, currently
in Phase 2B studies in RA and about to enter Phase 2 studies in Crohn's
disease. AbbVie and Galapagos signed a worldwide license agreement whereby
AbbVie will be responsible for further development and commercialization after
Phase 2B. Galapagos has another selective JAK1 inhibitor in Phase 2 in lupus
and psoriasis, GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in
2012). GLPG0974 is the first inhibitor of FFA2 to be evaluated clinically for
the treatment of IBD; this program is currently in a Proof-of-Concept Phase 2
study. GLPG1205 is a first-in-class molecule that targets inflammatory
disorders and is currently in a First-in-Human Phase 1 study.
The Galapagos Group, including fee-for-service companies BioFocus, Argenta and
Fidelta, has 800 employees and operates facilities in five countries, with
global headquarters in Mechelen, Belgium. Further information at: www.glpg.com
CONTACTS
Galapagos NV
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir(at)glpg.com
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
Galapagos appoints David Smith as CEO of Service Division:
http://hugin.info/133350/R/1723713/574489.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE
[HUG#1723713]
Unternehmensinformation / Kurzprofil:
Datum: 20.08.2013 - 07:31 Uhr
Sprache: Deutsch
News-ID 289092
Anzahl Zeichen: 6294
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 257 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos appoints David Smith as CEO of Service Division"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
